Histogen
Histogen Inc. was a San Diego-based, publicly traded regenerative medicine company developing a biological platform to replace and regenerate tissues in the body, targeting unmet needs in tissue repair before entering wind-down proceedings by 2026.
- Company typePublic
- Founded2007
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Histogen does
Histogen Inc. was a publicly traded regenerative medicine company headquartered in San Diego, California, founded in 2007. The company operated on a 'novel biological platform that replaces and regenerates tissues in the body,' positioning itself to address unmet medical needs in tissue regeneration and repair across multiple medical conditions. Its core technology centered on regenerative therapeutics, with clinical development allocated to advancing therapies targeting tissue repair; however, no specific products, FDA approvals, or commercial launches are documented in the available data, indicating a clinical-stage profile that never reached meaningful commercialization.
The company's business model relied on capital markets rather than product revenue. It funded operations through a series of equity and preferred stock issuances — including $24.9M (2015), $6.0M (2016), $14.0M (2020), $6.5M (2021), $4.75M (2022), and $5.0M (2022) — supplemented by non-dilutive grants from the National Science Foundation and the U.S. Department of War. In May 2020, Histogen acquired Conatus Pharmaceuticals for an undisclosed amount, broadening its clinical pipeline. The company maintained a small footprint of 11-50 employees and never disclosed named customers, recurring revenue, or a go-to-market motion, consistent with pre-commercial biotech operations.
By early 2026, Histogen had entered the final phase of its wind-down process, with a court date scheduled for March to address asset recovery proceedings. The company was delisted from NASDAQ under ticker HSTO. Its listed leadership spanned President & CEO Richard Pascoe, Founder and Scientific Advisor Gail K. Naughton, Executive Chairman and Interim President & CEO Steven J. Mento, and SVP of Tech Ops Martin Latterich. Iterative small financings under deteriorating conditions and the absence of commercial revenue signal that the company was unable to advance its pipeline to a self-sustaining stage.
Histogen firmographics
Firmographics- Name
- Histogen
- Legal name
- Histogen Inc.
- Website
- https://histogen.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Short description
- Histogen Inc. was a San Diego-based, publicly traded regenerative medicine company developing a biological platform to replace and regenerate tissues in the body, targeting unmet needs in tissue repair before entering wind-down proceedings by 2026.
- Ownership category
- akta.pro rank
Histogen industry classification
Industry- Product category
- Regenerative Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- akta.pro primary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
- akta.pro secondary industries
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Stem Cell–Based Regenerative Therapies (HLAAAGAA)
Keywords
Where Histogen is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Histogen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel
Histogen product offering
Product offeringCore offering
Histogen is a regenerative medicine company developing a proprietary biological platform intended to replace and regenerate tissues in the body. The company focused on advancing regenerative therapeutics through clinical development and research, targeting unmet medical needs in tissue repair and regeneration.
Differentiator
Problem solved
Functional benefit
Products and services
- Regenerative Therapeutics Platform Proprietary biological platform designed to replace and regenerate tissues in the body, targeting unmet medical needs in tissue repair and regeneration. Intended for healthcare providers and patients requiring regenerative treatments.
Companies that use Histogen
Customer profileSegments1 record
Ideal customer profiles1 record
Histogen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Histogen partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights3 records
Histogen competitors and assessment
Company assessmentDirect peers
- Vericel Corporation: Vericel develops autologous cell therapies for cartilage repair (MACI) and severe burns, directly overlapping with Histogen's HST-003 cartilage regeneration program and skin regeneration efforts. It is a relevant peer given Histogen's focus on musculoskeletal regenerative biologics.
- Mesoblast Limited: Mesoblast develops allogeneic cell-based regenerative therapies (remestemcel-L, rexlemestrocel-L) targeting inflammatory and musculoskeletal conditions. Highly comparable as a publicly traded regenerative medicine company pursuing similar tissue repair indications.
- Athersys Inc. Athersys developed MultiStem, a multipotent adult progenitor cell therapy for regenerative indications including stroke and ARDS. Comparable as a clinical-stage cell therapy peer that has similarly faced capital and clinical-development headwinds.
- Capricor Therapeutics: Capricor is developing allogeneic cardiosphere-derived cell therapies (CAP-1002) for Duchenne muscular dystrophy and other indications. Comparable as a small-cap clinical regenerative medicine company with similar financing patterns.
- Pluristem Therapeutics: Pluristem developed placenta-derived cell therapy products (PLX-PAD, PLX-R18) for regenerative indications including muscle injury and hematologic disorders. Comparable small-cap regenerative cell therapy peer with similar clinical-stage profile.
- MiMedx Group: MiMedx develops and commercializes placental tissue allografts for wound care, surgical recovery, and regenerative applications. Comparable regenerative medicine peer with commercial products in adjacent tissue-repair indications.
Broad incumbents
- Smith & Nephew (Osiris Therapeutics legacy): Smith & Nephew acquired Osiris Therapeutics in 2019 and continues to develop and market regenerative wound care and orthobiologic products. Functions as a broad incumbent in the regenerative medicine space where Histogen operated.
Emerging players
- Caladrius Biosciences: Caladrius is developing CD34+ cell-based regenerative therapies for ischemic conditions. A small emerging regenerative medicine peer pursuing tissue-repair mechanisms similar to Histogen's platform approach.
- InGeneron Inc. InGeneron develops autologous regenerative cell therapies using adipose-derived stem cells for orthopedic and wound healing indications. Comparable niche regenerative cell therapy company targeting musculoskeletal applications like Histogen's HST-003.
- Fortify Biosciences: Fortify is a regenerative tissue engineering company developing bioengineered constructs for cartilage and other musculoskeletal repair. Comparable emerging peer in cartilage and musculoskeletal regeneration where Histogen's HST-003 was positioned.
Market position
Strengths3 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Histogen social profiles
Digital presenceHistogen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Histogen leadership team
Management profileNumber of profiles
Profiles4 records
Histogen funding detail
Funding detailFunding overview
Funding rounds14 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Histogen M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Histogen
What does Histogen do?
Histogen is a regenerative medicine company developing a proprietary biological platform intended to replace and regenerate tissues in the body. The company focused on advancing regenerative therapeutics through clinical development and research, targeting unmet medical needs in tissue repair and regeneration.
Is Histogen a public or private company?
Histogen is a public company. It is classified as public and is currently closed.
When was Histogen founded?
Histogen was founded in 2007. It employs 11 to 50 people.
Where is Histogen based?
Histogen is headquartered in San Diego, United States, in the North America region.
Who are Histogen's main competitors?
Direct peers on record are Vericel Corporation, Mesoblast Limited, Athersys Inc., Capricor Therapeutics, Pluristem Therapeutics and MiMedx Group. Smith & Nephew (Osiris Therapeutics legacy) is listed as a broad incumbent. Emerging players are Caladrius Biosciences, InGeneron Inc. and Fortify Biosciences.
Does Histogen have an API?
No public API is recorded for Histogen.
What industry is Histogen in?
Histogen's product category is Regenerative Therapeutics. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414.